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The MTL is a relatively small structure, but is the most epileptogenic region of the human brain. It is hidden deep within the brain and has consider-
able anatomical complexity. Brain tumors arising from 
the MTL have been a formidable disease because of the 
difficulty of surgical removal and associated morbidity 
and mortality rates.
Brain tumors in the MTL have several distinct char-
acteristics. First, the proportion of pathological charac-
teristics of benign (low-grade) lesions is greater than for 
tumors in other locations in the brain. Many low-grade 
brain tumors, such as DNET and PXA, tend to be located 
in the temporal lobe, whereas malignant gliomas develop 
evenly in proportion to the volume of the brain. Second, 
the majority of patients with an MTL brain tumor present 
with epileptic seizures, and many of them suffer from 
chronic drug-resistant epilepsy. Third, although the MTL 
is a complex structure, anatomical disconnection and en 
bloc resection of this region can be achieved by experi-
enced surgeons and can result in low morbidity rates.
Following the seminal report on the surgery of lim-
bic system tumors by Yaşargil et al.,21 advances in TLE 
surgery have improved the chance of a surgical cure 
for these tumors, with an acceptable level of complica-
tions.14,18 Schramm and Aliashkevich15 have described a 
practical classification of MTL tumors, allowing for pre-
operative surgical planning and objective evaluation of 
the outcome. However, the number of articles on brain 
tumors in the MTL is limited at present, and previous 
studies have focused on immediate surgical outcomes 
and complication rates.14,18,21 This narrow interest is part-
ly attributed to the substantial technical difficulty of the 
operative procedures per se, and to the ongoing contro-
versies concerning the optimal surgical approach. We an-
alyzed the long-term surgical outcome in 36 patients with 
an MTL tumor, with emphasis on tumor control. Clinical 
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Object. Surgical treatment of brain tumors in the mesial temporal lobe (MTL) is a highly demanding procedure. 
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Methods. Thirty-six patients with an MTL tumor were studied. The mean patient age at surgery was 32 years 
(range 13–62 years). The tumors were confined to the MTL (Schramm Type A) in 25 patients (69%). Extension of 
the tumor into the fusiform gyrus (Schramm Type C) and temporal stem (Schramm Type D) was observed in 4 and 7 
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actuarial progression-free survival rates were 97% in the 1st year, 84% in the 2nd year, and 80% in the 5th year. The 
degree of tumor resection was significantly related to the tumor control failure (p < 0.001) and malignant transforma-
tion of a low-grade tumor (p < 0.001). Univariate analyses using a Cox proportional hazards model showed that the 
following factors were significantly associated with a failure to control the tumor: 1) extent of the tumor (Schramm 
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≥ 50 years (p = 0.007, RR 8.312); and 4) short duration of epilepsy (< 6 months; p = 0.001, RR 21.54).
Conclusions. Surgery is the principal treatment for MTL tumors, despite its technical difficulty. Complete tumor 
resection is strongly recommended for long-term tumor control. The MTL tumors are heterogeneous in their prog-
nosis. Older age, short duration of epilepsy, and tumor size are all associated with poor outcome. Patients with these 
characteristics may have a more aggressive form of the disease than those with MTL tumors associated with chronic 
epilepsy. (DOI: 10.3171/2009.5.FOCUS09106)
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factors affecting the outcome were examined, with par-
ticular emphasis on the predictive value of the Schramm 
classification of this lesion.
Methods
Patient Population
We studied patients who had undergone surgery for 
an MTL tumor at the Seoul National University Hospital 
between January 1995 and December 2007. All patients 
were selected from the epilepsy surgery database. Only 
primary intraaxial tumors were included, and extraaxial 
tumors, such as meningiomas or schwannomas, were ex-
cluded. Patients who received initial resection at another 
institution were also excluded. The MTL is medial to the 
collateral or the rhinal sulci and includes the amygdala, 
hippocampus, uncus, and parahippocampal gyrus. Tu-
mors arising from the fusiform gyrus without involvement 
of the MTL were excluded. Thirty-six patients with an 
intraaxial tumor in the MTL were included in our study. 
Twenty-three patients were male and 13 were female, and 
the mean age of these patients at surgery was 32 years 
(range 13–62 years). We retrospectively reviewed the 
clinical data of these individuals.
All patients presented with epileptic seizures. The 
seizures were drug-resistant in 20 patients but were ad-
equately controlled with antiepileptic drugs in the other 
16. The median age at seizure onset was 20.5 years (range 
6–62 years), with a median duration of epilepsy of 3 years 
(range 1 month–48 years). No neurological deficits were 
observed at presentation in any patients.
All patients received a diagnostic workup for the 
definition of epileptogenic zones, including brain MR 
imaging, FDG-PET, electroencephalography, and neu-
ropsychological tests. These diagnostic workups were 
minimized and customized for tumor surgery in patients 
≥ 50 years of age and with a short period of epilepsy. 
The MR images were obtained using a 1.5-T MR imaging 
unit, with a protocol that incorporated axial and coronal 
T2- and FLAIR-weighted images.
Tumor Characteristics
Twenty-seven patients (75%) had a tumor in the left 
temporal lobe, and 9 (25%) had a tumor in the right tem-
poral lobe. We classified the tumors according to the 
scheme suggested by Schramm and Aliashkevich.15 Be-
cause we did not include tumors in the fusiform gyrus 
without involvement of the MTL, no Schramm Type B 
tumors (basal tumors in the fusiform gyrus) were in-
cluded. Twenty-five tumors (69%) corresponded to Sch-
ramm Type A (MTL tumors involving the amygdala, 
hippocampus, uncus, or parahippocampal gyrus). Four 
tumors (11%) corresponded to Schramm Type C (tumors 
involving both the MTL and fusiform gyrus). Seven tu-
mors (19%) that invaded the temporal stem and extended 
into the lateral basal ganglia or insular lobe were defined 
as Schramm Type D (Fig. 1). Tumor size was measured 
using both axial and coronal MR images, and the largest 
diameter was recorded. The mean tumor sizes were 22, 
 Fig. 1. Coronal images demonstrating the extent of MTL tumors classified according to Schramm and Aliashkevich (2008).  
Left: A Schramm Type A tumor restricted to the MTL, medial to the collateral or rhinal sulci; it is a DNET involving the left amygdala.  
Center: A Schramm Type C tumor affecting both the MTL and fusiform gyrus. It is a ganglioglioma involving both the parahip-
pocampal gyrus and fusiform gyrus, crossing over to the collateral sulcus. Right: A Schramm Type D tumor invading the 
temporal lobe stem into the lateral basal ganglia or insular lobe. It is a ganglioglioma involving the MTL, temporal lobe stem, and 
insular lobe.
Fig. 2. Bar graph showing a comparison of tumor size with Schramm 
type. The mean tumor size of Schramm Type A was 22 mm, Type C 
was 32 mm, and Type D was 40 mm; the tumor size was significantly 
different between the groups (p = 0.001, Kruskal-Wallis test). Error bars 
indicate SEMs.
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32, and 40 mm for Schramm Types A, C, and D tumors, 
respectively, showing a significant difference in the tumor 
size according to the Schramm types (p = 0.001, Kruskal-
Wallis test) (Fig. 2).
Surgical Approaches
Various surgical approaches were adopted for the 
radical resection of these tumors. Anterior temporal lo-
bectomy was the most common procedure (23 tumors, 
64%), followed by temporal polar resection (lateral tem-
poral resection < 3 cm in 8 tumors, 22%), transsylvian 
approach (4 tumors, 11%), and transsuperior temporal 
gyrus approach (1 tumor, 3%). The operative strategies 
for tumor-related TLE were described in our previous 
article.10 The primary concern was tumor control, espe-
cially in the patients with medically controlled epilepsy. 
Fig. 3. Preoperative and postoperative MR images demonstrating a Schramm Type D oligodendroglioma in a 62-year-old 
man. A and B: Preoperative T2-weighted axial and coronal images. The tumor involves the MTL (amygdala, hippocampus, 
and fusiform gyrus) and extends into the temporal stem. C and D: Postoperative T2-weighted axial and coronal images. The 
resection was incomplete (subtotal resection). Small residual tumors are identified in the posterior hippocampal resection margin 
and in the temporal stem (arrows). The patient immediately received radiation therapy, but the tumor progressed 15 months after 
the operation.
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If the tumor involved the hippocampus, it was resected in 
all patients except 1, who refused hippocampectomy to 
preserve memory. Radical tumor resection was therefore 
attempted in all except this patient.
The extent of tumor removal was evaluated by post-
operative MR imaging obtained within 3 months of 
the operation. Gross-total removal was achieved in 26 
patients (72%). Removal was incomplete in 10 patients 
(28%); of these, 8 had subtotal resection (> 90% of tumor 
volume) and 2 had partial resection (50–90% of tumor 
volume) (Fig. 3).
Pathology and Adjuvant Treatment
Ganglioglioma was the most common tumor (13 le-
sions, 36%), followed by DNET (9 tumors, 25%), oligo-
dendroglioma (6 tumors, 17%), and diffuse astrocytoma 
(5 tumors, 14%). Miscellaneous tumors included anaplas-
tic astrocytoma, choroid plexus papilloma, and PXA, with 
1 case each. All lesions were low-grade tumors defined as 
WHO Grade I or II, except 1 anaplastic astrocytoma. The 
patient with this tumor received adjuvant chemotherapy 
and radiation therapy immediately after a subtotal resec-
tion. Another patient with a partially resected oligoden-
droglioma received postoperative radiation therapy.
Follow-Up and Statistical Analyses
The median follow-up period was 50.5 months (range 
7–129 months). Neurological status was assessed in the 
outpatient clinic. Brain MR imaging was performed at 
regular intervals, ranging from 3 months to 1 year, ac-
cording to the pathological diagnosis and the degree of 
tumor removal. Twenty-four patients (67%) are currently 
receiving follow-up care in the outpatient clinic. We have 
concentrated on assessing and analyzing the oncological 
outcome, because we have comprehensively dealt with 
the seizure outcome in patients with tumor-related TLE 
in our previous article.10
The PFS rate was calculated using the Kaplan-Meier 
method. A log-rank test was used for univariate analy-
ses. A Cox proportional hazards model was applied for 
uni- and multivariate analyses. A nonparametric analysis 
(Kruskal-Wallis test) was applied to compare continuous 
variables between multiple groups. The level of signifi-
cance was taken as 5%.
Results
To calculate the crude cumulative rate of tumor con-
trol, the end point was set when a recurrence was docu-
mented on the follow-up MR imaging or when the residu-
al tumor had progressed (tumor volume increased > 25% 
in the follow-up MR imaging). The actuarial PFS rates 
were 97% in the 1st year, 84% in the 2nd year, and 80% in 
the 5th year (Fig. 4). Seven patients (19%) experienced tu-
mor control failure (progression of the disease) during the 
follow-up period. The pathological findings in the tumors 
that were not controlled were ganglioglioma (3 cases), oli-
Fig. 4. Chart showing survival function of tumor control calculated 
with the Kaplan-Meier method. The actuarial PFS rates were 97% in the 
1st year, 84% in the 2nd year, and 80% in the 5th year.
Fig. 5. Charts showing survival functions of tumor control according to the degree of surgical removal and the preoperative 
extent of the lesions. Left: Tumor control was significantly influenced by the degree of tumor removal (p < 0.001, log-rank 
test). Right: The extent of the tumors estimated by the Schramm types was also significantly associated with tumor control (p 
= 0.001, log-rank test). Ad hoc analysis revealed that Schramm Type D tumors were significantly more difficult to control than 
Schramm Types A and C tumors.
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godendroglioma (2), anaplastic astrocytoma (1), and PXA 
(1). Six of the 7 uncontrolled tumors were incompletely 
resected during the initial operation. One ganglioglioma 
recurred 6 years after complete removal of the tumor.
Kaplan-Meier survival functions showed that the tu-
mor control was significantly affected by the degree of 
tumor resection (p < 0.001, log-rank test). The extent of 
the tumors estimated by the Schramm types was also sig-
nificantly associated with tumor control (p = 0.001, log-
rank test). Ad hoc analysis showed that Schramm Type D 
tumors were significantly more difficult to control than 
Schramm Types A and C lesions (Fig. 5). A Schramm 
Type D classification, larger tumor size, incomplete re-
section, and failure to control the tumor were all signifi-
cantly correlated variables (r > 0.3 and p < 0.05 for all 
combinations; Pearson correlation) (Table 1).
Univariate analyses using a Cox proportional hazards 
model showed that among the various preoperative clini-
cal variables, the extent of the tumor (Schramm Type D), 
its size, the patient’s age at surgery, and shorter duration 
of epilepsy were all significantly associated with failure 
to control the tumor. Preoperative duration of epilepsy 
as a continuous variable was not a significant prognostic 
factor, but epilepsy lasting < 6 months was a strong nega-
tive factor (p = 0.001, RR 21.54; Cox regression analysis) 
(Table 2). Multivariate analyses using the same model re-
vealed no significant preoperative prognostic factors pre-
dicting tumor control failure.
Malignant progression (transformation) of a low-
grade tumor occurred in 4 patients during the follow-up 
period. The actuarial malignant PFS in the 5th year was 
88%. The initial pathological diagnoses in these patients 
were as follows: a low-grade ganglioglioma in 2, an oli-
godendroglioma in 1, and a PXA in 1 patient. Malignant 
transformation of the tumor was pathologically confirmed 
in 2 patients. The other 2 showed typical radiological fea-
tures of malignant transformation (emergence of rim-en-
hancing masses or diffuse leptomeningeal seeding). The 
initial resection was incomplete in all these patients. The 
malignant PFS was significantly influenced by the degree 
of initial resection (p < 0.001, log-rank test) (Fig. 6).
Three patients succumbed to the disease during the 
follow-up period: 1 had an anaplastic astrocytoma, in 1 
the ganglioglioma had transformed into a glioblastoma, 
and 1 had a PXA that transformed with diffuse leptomen-
ingeal seeding. The actuarial overall survival rate in the 
5th year was 90%.
Discussion
The MTL is part of the limbic lobe and is charac-
terized by a distinct cellular architecture and distinct 
TABLE 1: Correlations between the extent of the tumor, tumor size, incomplete resection, and tumor control failure
Factor Statistics
Schramm 





Schramm Type D Pearson coefficient (r value) 1 0.543 0.479 0.645
p value 0.001 0.003 <0.001
tumor size Pearson coefficient (r value) 0.543 1 0.518 0.363
p value 0.001 0.001 0.030
incomplete resection Pearson coefficient (r value) 0.479 0.518 1 0.636
p value 0.003 0.001 <0.001
tumor control failure Pearson coefficient (r value) 0.645 0.363 0.636 1
p value <0.001 0.030 <0.001
Fig. 6. Kaplan-Meier survival plots depicting malignant PFS, assessed in 35 patients with a low-grade tumor. Left: Malignant 
progression (transformation) of the tumor occurred in 4 patients; the actuarial malignant PFS in the 5th year was 88%. Right: 
The malignant PFS was also significantly influenced by the degree of tumor removal (p < 0.001, log-rank test).
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anatomical connections.21 Many kinds of brain tumors 
develop in the MTL. Low-grade brain tumors, such as 
ganglioglioma, DNET, and diffuse fibrillary astrocytoma, 
are the most common tumors of the MTL.14 The frequent 
occurrence of these low-grade brain tumors in the MTL, 
a relatively small region in the human brain, may be at-
tributed to the presence of the subependymal plate lying 
along the temporal horn and the subgranular layer in the 
hippocampus, where uncommitted neuroglial progenitors 
exist through childhood to adulthood.5 Epileptic seizures 
are more common in low-grade tumors than in high-grade 
ones.19 Tumors of a mixed glioneuronal character, such as 
ganglioglioma and DNET, are frequently associated with 
cortical dysplasia, an epileptogenic developmental anom-
aly.13 Therefore, brain tumors are one of the main causes 
of TLE, and surgical outcome of the MTL tumors has 
been chiefly addressed in studies of TLE surgery.3,4
Several authors have described the surgical outcomes 
of MTL tumors from an oncological perspective.14,18,20 
These studies have included a substantial number of ma-
lignant brain tumors, such as anaplastic astrocytomas, 
glioblastomas, and metastatic tumors, broadening the 
interest from epilepsy surgery to include oncology. De-
spite the heterogeneity of the pathological entities, MTL 
tumors can be viewed as a group by neurosurgeons for the 
following reasons. First, the pathological findings and tu-
mor grade cannot be accurately predicted preoperatively, 
and resection is the initial treatment most resorted to for 
MTL tumors. Second, most brain tumors are more or less 
resistant to adjuvant therapies, and resection is currently 
the principal treatment. Third, MTL tumors, especially 
those with the pathological characteristics of low-grade 
lesions, tend to be restricted to the anatomical boundary 
of the temporal lobe, and complete removal of them is 
possible in many cases. Last, in many cases, in toto tem-
poral lobe resection is required for seizure control. There-
fore, complete resection is an important goal for the treat-
ment of MTL tumors. Most brain tumors tend to progress 
eventually following incomplete resection. Although 
some authors have reported that DNETs remain quies-
cent following incomplete removal, in a previous study 
we have reported 2 cases of recurrence of DNET arising 
from the lateral temporal lobe.10 The completeness of tu-
mor removal is known to be a major prognostic factor for 
both low- and high-grade gliomas in many studies.9,11,17
All of our patients except 1 had a low-grade brain 
tumor (WHO Grade I or II), whereas previous MTL tu-
mor studies included a greater proportion of malignant 
tumors (22–44%).14,18,20 The homogeneity of our cases al-
lows us to analyze long-term outcomes. However, there 
is still inherent heterogeneity in the low-grade pathologi-
cal findings, with prognostic implications. Therefore, we 
focused on the PFS rather than overall survival, because 
PFS reflects the direct influence of surgery rather than 
the overall survival, which may be affected by subsequent 
treatment and the biological behavior of the tumor.
Analyses of the PFS and relevant preoperative prog-
nostic factors in this study revealed 2 distinct facts. First, 
the extent of an MTL tumor was a significant risk factor 
for the progression of the disease. Schramm and Aliash-
kevich15 proposed the classification of mesiobasal tempo-
ral lobe tumors based on the MR imaging study of hun-
dreds of cases. Tumor size and the proportion of those 
with malignant histological findings increased according 
to the Schramm types.14 Schramm Type D tumors that 
extend beyond the MTL into the diencephalon, insular 
lobe, and temporal neocortex represent more aggressive 
disease. Complete resection of these tumors is difficult 
and precarious in many cases.14 We found that Schramm 
Type D tumors were associated with incomplete resection 
and subsequent progression.
Second, a patient age ≥ 50 years with a duration of 
epilepsy < 6 months was associated with a poor progno-
sis. This finding amply reflects the heterogeneity of the 
study population, which included patients with chron-
ic epilepsy as well as those with simple tumors. It has 
been proposed that brain tumors associated with chronic 
epilepsy have a better prognosis than tumors in patients 
without epilepsy.8,12 Some authors have suggested that 
this phenomenon is related to different tumor histopatho-
logical characteristics.16 However, this phenomenon may 
reflect a selection bias, because chronic epilepsy lasting 
for years without significant disease progression is de 
facto evidence of a slowly growing benign lesion. Patient 
age is a more reliable prognostic factor in neurooncology. 
Gliomas behave more malignantly with increasing patient 
age, both quantitatively and qualitatively. In the pediatric 
population, the majority of gliomas are low-grade tumors, 
and even glioblastomas have a better prognosis than those 
of adulthood.2,6 Young age is also associated with a longer 
TABLE 2: Relative risks for tumor control failure estimated with a Cox proportional hazards model*
Factor
Univariate Analysis Multivariate Analysis
p Value Crude RR 95% CI p Value Adjusted RR 95% CI
laterality (lt MTL) 0.704 0.727 0.140–3.772 NA NA NA
extent of tumor (Schramm Type D) 0.003 12.04 2.317–62.53 0.261 3.611 0.385–33.92
tumor size (mm) 0.033 1.052 1.004–1.101 0.643 0.985 0.926–1.049
age at op (continuous variable) 0.036 1.059 1.004–1.118 NA NA NA
age at op ≥ 50 yrs 0.007 8.312 1.788–38.64 0.236 3.108 0.476–20.29
duration of epilepsy (continuous variable) 0.864 1.006 0.942–1.073 NA NA NA
duration of epilepsy < 6 mos 0.001 21.54 3.647–127.2 0.056 8.313 0.926–1.049
* NA = not assessed.
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survival in patients with low-grade gliomas.1,7 Therefore, 
as for MTL tumors, older patients with a short symptom 
duration may experience a more aggressive form of the 
disease associated with a larger and more infiltrative tu-
mor, although the initial pathological examination might 
show the presence of a low-grade tumor.
Conclusions
Surgery is the principal treatment for MTL tumors, 
despite its technical difficulty. Complete tumor removal is 
strongly recommended for long-term tumor control. Older 
patient age, short symptomatic duration, large tumor size, 
and tumor invasion beyond the MTL are associated with 
poor outcome. Patients with these characteristics may ex-
perience a more aggressive disease than MTL tumors as-
sociated with chronic epilepsy.
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